Willingness of patients with biochemically recurrent prostate cancer (BCR) with positive 18F-dcfpyl PET/CT PSMA to monitor without treatment.
Monique Williams(National Institutes of Health), Ravi A. Madan(National Cancer Institute), Amy Hankin(National Institutes of Health), Laura A. Sena(Johns Hopkins University), Esther Mena Gonzalez(National Cancer Institute), Philip M. Arlen(Dana-Farber Cancer Institute), Megan Hausler(National Institutes of Health), Liza Lindenberg(National Cancer Institute), Peter L. Choyke(National Cancer Institute), Fatima Karzai(National Institutes of Health), Jeanny B. Aragon‐Ching(Inova Fairfax Hospital)
Cited by 0
Related Papers
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
|Nature Genetics|1997|1.5k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|975
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
|Clinical Cancer Research|2018|415
American Cancer Society prostate cancer survivorship care guidelines
|CA A Cancer Journal for Clinicians|2014|402